Travere Therapeutics (TVTX) Insider Trading & Ownership $17.86 +0.47 (+2.70%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Travere Therapeutics (NASDAQ:TVTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.06%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$1.94 M Get TVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Travere Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TVTX Insider Buying and Selling by Quarter Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Travere Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/4/2024Gary A LyonsDirectorSell40,000$14.73$589,200.00 9/30/2024Jeffrey A MecklerDirectorSell40,000$14.06$562,400.00 9/9/2024Christopher R ClineCFOSell2,490$11.52$28,684.80 9/9/2024Eric M DubeCEOSell21,125$11.52$243,360.00 9/9/2024Jula InrigInsiderSell2,191$11.52$25,240.32 9/9/2024William E RoteSVPSell4,387$11.52$50,538.24 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/4/2024Christopher R ClineCFOSell514$9.51$4,888.14 4/11/2024Christopher R ClineCFOSell54$6.74$363.96 2/1/2024Christopher R ClineCFOSell3,818$8.53$32,567.54 2/1/2024Eric M DubeCEOSell19,122$8.70$166,361.40 2/1/2024Peter HeermaInsiderSell4,195$8.53$35,783.35 2/1/2024Sandra CalvinCAOSell2,820$8.53$24,054.60 2/1/2024William E RoteSVPSell4,764$8.71$41,494.44 1/23/2024Christopher R ClineCFOSell853$9.07$7,736.71 1/23/2024Elizabeth E ReedSVPSell2,062$8.96$18,475.52 1/23/2024Eric M DubeCEOSell7,873$8.96$70,542.08 1/23/2024Peter HeermaInsiderSell1,559$9.07$14,140.13 1/23/2024Sandra CalvinCAOSell910$9.07$8,253.70 1/3/2024Jula InrigInsiderSell2,069$9.48$19,614.12 (Data available from 1/1/2013 forward) TVTX Insider Trading Activity - Frequently Asked Questions Who is on Travere Therapeutics's Insider Roster? The list of insiders at Travere Therapeutics includes Christopher R Cline, Elizabeth E Reed, Eric M Dube, Gary A Lyons, Jeffrey A Meckler, Jula Inrig, Laura Clague, Peter Heerma, Sandra Calvin, Steve Aselage, and William E Rote. Learn more on insiders at TVTX. What percentage of Travere Therapeutics stock is owned by insiders? 4.06% of Travere Therapeutics stock is owned by insiders. Learn more on TVTX's insider holdings. Which Travere Therapeutics insiders have been selling company stock? The following insiders have sold TVTX shares in the last 24 months: Christopher R Cline ($142,719.90), Elizabeth E Reed ($89,789.77), Eric M Dube ($983,379.28), Gary A Lyons ($589,200.00), Jeffrey A Meckler ($562,400.00), Jula Inrig ($87,412.69), Peter Heerma ($148,062.48), Sandra Calvin ($95,705.29), and William E Rote ($163,064.33). How much insider selling is happening at Travere Therapeutics? Insiders have sold a total of 207,698 Travere Therapeutics shares in the last 24 months for a total of $2,861,733.74 sold. Travere Therapeutics Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Compensation: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Compensation: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Compensation: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Compensation: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Compensation: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business Officer More Insider Trading Tools from MarketBeat Related Companies Harrow Insider Trading Rigel Pharmaceuticals Insider Trading Omeros Insider Trading Crinetics Pharmaceuticals Insider Trading Avidity Biosciences Insider Trading Krystal Biotech Insider Trading ADMA Biologics Insider Trading TG Therapeutics Insider Trading Biohaven Insider Trading Arcellx Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:TVTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
